Oct. 25 at 7:42 PM
$NWBO @Makeitcometrue
An increase of approximately 18% in overall survival, from 16 to 19 months, is clinically relevant and statistically significant, especially in oncology where even modest gains can reflect meaningful therapeutic progress.
And now the mMGMT mOS: We have 30.2 mos from randomization vs 21.3 mos from randomization in controls. A + of 9 month is highly significant and indicates a strong therapeutic effect. We are talking about an increase of 41 %!
The rGBM numbers will definitely blow your little brain away!
One more thing: In the last 17 and 27 years, respectively, one drug has achieved an increase of +2 months for nGBM, and one drug has achieved an increase of +2 months for rGBM!
Welcome to the revolution!!